Geron Corporation was the big hope for embryonic-stem-cell research. After years of promises, its first-ever human trial using an embryonic-stem-cell-derived product for acute spinal-cord injury made huge headlines internationally. But now, the Washington Post is reporting that Geron has abandoned the field altogether.
This is an atom bomb of a story that will have a serious effect on the entire regenerative medical sector. And it should embarrass the critics of President Bush; the California Institute for Regenerative Medicine, which bragged about its part in funding a scientist involved in the research; and, perhaps most of all, the fawning media that have acted as press agent for both the field generally, and Geron specifically.